文献速递肝病消化道肿瘤与早癌

肝细胞癌动脉内伊达比星-碘油乳剂无栓塞治疗:LIDA-BⅠ期临床试验

Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.
PubMed 文献 · J Hepatol · 2018-02-08

LIDA-BⅠ期剂量递增试验在肝硬化肝细胞癌患者中评估伊达比星-碘油乳剂经动脉给药(不栓塞)的最大耐受剂量、安全性、疗效与药代动力学。15例患者接受两次治疗,最大耐受剂量为20 mg;仅2例出现剂量限制性毒性;客观缓解率29%,中位疾病进展时间5.4个月,中位总生存期20.6个月。

要点

  • 伊达比星-碘油乳剂经动脉给药不栓塞的最大耐受剂量为20 mg。
  • 15例中仅2例出现剂量限制性毒性:20 mg组水肿性腹腔积液失代偿,25 mg组腹痛。
  • 第二次治疗1个月后客观缓解率29%(完全缓解0%,部分缓解29%),中位疾病进展时间5.4个月,中位总生存期20.6个月。

核心结论

  • 两次化学碘油栓塞治疗(不栓塞)后伊达比星的最大耐受剂量为20 mg。
  • 观察到令人鼓舞的安全性结果以及患者缓解和生存。
  • 已计划开展Ⅱ期试验。

研究设计与样本

  • 剂量递增Ⅰ期试验,在肝硬化肝细胞癌患者中进行。
  • 患者接受两次经动脉伊达比星-碘油乳剂治疗,不栓塞。
  • 伊达比星剂量按改良连续再评估法递增。
  • 最大耐受剂量定义为最接近导致20%患者出现剂量限制性毒性的剂量。
  • 共入组15例患者:10 mg组1例,15 mg组4例,20 mg组7例,25 mg组3例。

主要发现

  • 仅2例患者出现剂量限制性毒性:20 mg组水肿性腹腔积液失代偿,25 mg组腹痛。
  • 计算的最大耐受剂量为20 mg。
  • 最常见的≥3级不良事件为生物学异常。
  • 第二次治疗1个月后,基于改良实体瘤疗效评价标准,客观缓解率为29%(完全缓解0%,部分缓解29%)。
  • 中位疾病进展时间为5.4个月(95%CI 3.0-14.6个月),中位总生存期为20.6个月(95%CI 5.7-28.7个月)。

关键数值与推荐

  • 最大耐受剂量定义为最接近导致20%患者出现剂量限制性毒性的剂量。
  • 计算的伊达比星最大耐受剂量为20 mg。
  • 客观缓解率29%(完全缓解0%,部分缓解29%),基于改良实体瘤疗效评价标准。
  • 中位疾病进展时间5.4个月(95%CI 3.0-14.6个月),中位总生存期20.6个月(95%CI 5.7-28.7个月)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Idarubicin shows high cytotoxicity against hepatocellular carcinoma (HCC) cells, a high hepatic extraction ratio, and high lipophilicity leading to stable emulsions with lipiodol. A dose-escalation phase I trial of idarubicin_lipiodol (without embolisation) was conducted in patients with cirrhotic HCC to estimate the maximum-tolerated dose (MTD) and to assess the safety, efficacy, and pharmacokinetics of the drug, and the health-related quality of life achieved by patients. METHODS: Patients underwent two sessions of treatment with a transarterial idarubicin_lipiodol emulsion without embolisation. The idarubicin dose was escalated according to a modified continuous reassessment method. The MTD was defined as the dose closest to that causing dose-limiting toxicity (DLT) in 20% of patients. RESULTS: A group of 15 patients were enrolled, including one patient at 10 mg, four patients at 15 mg, seven patients at 20 mg, and three patients at 25 mg. Only two patients experienced DLT: oedematous ascitic decompensation and abdominal pain at 20 and 25 mg, respectively. The calculated MTD of idarubicin was 20 mg. The most frequent grade ≥3 adverse events were biological. One month after the second session, the objective response rate was 29% (complete response, 0%; partial response, 29%) based on modified Response Evaluation Criteria In Solid Tumours. The median time to progression was 5.4 months [95% confidence limit (CI) 3.0-14.6 months] and median overall survival was 20.6 months (95% CI 5.7-28.7 months). Pharmacokinetic analysis of idarubicin showed that the mean Cmax of idarubicin after intra-arterial injection of the idarubicin-lipiodol emulsion is approximately half the Cmax after intravenous administration. Health-related quality of life results confirmed the good safety results associated with use of the drug. CONCLUSIONS: The MTD of idarubicin was 20 mg after two chemolipiodolisation sessions. Encouraging safety results, and patient responses and survival were observed. A phase II trial has been scheduled. LAY SUMMARY: There is a need for transarterial regimens that improve the responses and survival of patients with unresectable HCC. In this phase I trial, we showed that two sessions of treatment with a transarterial idarubicin_lipiodol emulsion without embolisation was well tolerated and gave promising efficacy in terms of tumour control and patient survival.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Guiu B, Jouve JL, Schmitt A, et al. Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. J Hepatol. 2018. PMID: 29427728. doi:10.1016/j.jhep.2018.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。